Welcome to our dedicated page for BioLineRx Ltd. SEC filings (Ticker: BLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BioLineRx Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BioLineRx Ltd.'s regulatory disclosures and financial reporting.
BioLineRx Ltd. (BLRX) is convening its Annual General Meeting of shareholders on September 23, 2026, in Modi’in, Israel. Holders of ordinary shares and American Depositary Shares (ADSs), each representing 600 ordinary shares, at the close of business on August 24, 2026, are entitled to vote.
Shareholders will vote on re-electing three Class III directors (Aharon Schwartz, Sandra Panem and Shaoyu Yan) to terms ending at the 2029 annual meeting, a major increase in authorized share capital from 20,000,000,000 to 100,000,000,000 ordinary shares (all at NIS 0.10 par value), equity-based compensation for CEO Philip Serlin (options and performance stock units) and option grants to most directors aligned with the existing compensation policy. They will also vote on reappointing Kesselman & Kesselman, a PwC network firm, as independent auditor for 2026 and authorizing the audit committee to set its fees.
As of August 10, 2026, 2,620,977,190 ordinary shares were outstanding, with additional shares reserved under equity plans and warrants, and officers and directors as a group beneficially owned 54,589,800 shares, or 2.01%. The company highlights that future share issuances under the expanded authorization could dilute voting power, market price and book value per share. 2025 audited financial statements will be presented for discussion but are not subject to a vote.
BioLineRx and Hemispherian report new preclinical data showing strong synergy between GLIX1 and the PARP inhibitor olaparib in a patient-derived ovarian cancer xenograft model. Low-dose combination therapy delivered substantially better efficacy than controls and than each drug alone at its optimal dose, and showed efficacy comparable to cisplatin.
The data support synthetic lethality between GLIX1 and PARP inhibitors in homologous recombination-proficient ovarian cancer, a large group that responds poorly to current PARP inhibitor therapy. Based on these results, BioLineRx plans to add an ovarian cancer arm to the expansion part of its ongoing Phase 1/2a GLIX1 trial.
GLIX1 is a first-in-class, oral small molecule that activates the TET2 pathway to overwhelm cancer DNA repair and induce cell death. It is already in a Phase 1/2a trial in glioblastoma and other high-grade gliomas, with updates expected in H2 2026 and full dose-escalation results anticipated in 2027.
BioLineRx reported first quarter 2026 results showing a net loss of $2.6M, compared with net income of $5.1M a year earlier, as research and development spending increased. Royalty revenue from partnerships rose to $0.5M, reflecting initial APHEXDA commercialization.
Cash, cash equivalents and short-term deposits totaled $17.4M as of March 31, 2026, with negative operating cash flow of $2.3M for the quarter. Management expects existing resources to fund operations into the first half of 2027, but explicitly notes material uncertainty that may cast significant doubt on the company’s ability to continue as a going concern.
Strategically, BioLineRx is pivoting to an R&D-focused model centered on oncology and rare diseases. The lead asset GLIX1 advanced with the first patient dosed in a Phase 1/2a glioblastoma trial, backed by encouraging preclinical data and Orphan Drug Designation in the US and EU. Motixafortide, already approved as APHEXDA for stem-cell mobilization, is now out-licensed globally, while the company retains development rights in solid tumors including metastatic pancreatic cancer supported by an ongoing Phase 2b trial.
BioLineRx Ltd. furnished a report highlighting new scientific data and clinical plans for GLIX1, its lead oncology program, in collaboration with Hemispherian AS. Two abstracts on GLIX1 will appear at the ASCO 2026 Annual Meeting, covering its novel TET2-targeting mechanism and synergy with PARP inhibitors across multiple cancers.
Preclinical studies show GLIX1 is an oral, brain-penetrant small molecule that restores TET2 activity, induces tumor-selective DNA damage, demonstrates antitumor activity in glioblastoma models, and was well tolerated in animal safety studies. A first-in-human Phase 1/2a trial in recurrent and progressive glioblastoma and other high-grade gliomas is enrolling, with Part 1 expected to include up to 30 patients and establish a recommended dose.
BioLineRx anticipates trial updates in the second half of 2026 and full dose-escalation results in 2027, with Phase 2a expansion cohorts planned in newly diagnosed glioblastoma and selected other cancers, including combinations with standard-of-care regimens and PARP inhibitors.
BioLineRx Ltd. files a Form 6-K highlighting new preclinical data for GLIX1 in glioblastoma (GBM). Together with Hemispherian, the company reports that orally administered GLIX1 showed robust anti-tumor activity in multiple in‑vivo GBM models, including a temozolomide (TMZ)-resistant patient-derived xenograft model where TMZ showed no effect.
The data support a Phase 1/2a open-label, multicenter trial of GLIX1 in recurrent and progressive GBM and other high‑grade gliomas, with dose escalation enrolling up to 30 patients to determine a maximum tolerated or recommended dose. Trial updates are anticipated during H2 2026, with full dose‑escalation results expected in 2027 and later Phase 2a expansion into newly diagnosed GBM and select other cancers.
BioLineRx Ltd. filed a Form 6-K highlighting a joint update with Hemispherian AS that the first patient has been dosed in a first-in-human, Phase 1/2a trial of GLIX1 for recurrent and progressive glioblastoma and other high-grade gliomas.
The study, conducted at leading U.S. cancer centers including NYU Langone Health, will initially enroll up to 30 patients in a Phase 1 dose-escalation stage to determine a maximum tolerated or recommended dose based on safety, pharmacokinetics/pharmacodynamics and preliminary efficacy. Initial Phase 1 data are anticipated in the first half of 2027.
GLIX1 is described as an oral, first-in-class small molecule designed to activate TET2 and selectively induce DNA damage in cancer cells, with strong preclinical activity and blood-brain-barrier penetration. A Phase 2a expansion is planned in newly diagnosed glioblastoma and selected other cancers, including combinations such as with PARP inhibitors.
BioLineRx Ltd. director Yan Shaoyu has filed an initial Form 3 insider report. The data shows no reported transactions, with buy, sell, acquire, and dispose counts all at zero. The filing also lists no derivative positions and no holding entries in this snapshot.
BioLineRx Ltd. director Sandra Panem filed an initial ownership report showing multiple employee stock options to buy Ordinary Shares. The options cover blocks such as 199,800 shares at an exercise price of $0.356 and 1,080,000 shares at $0.085, with expirations between 2026 and 2034.
Footnotes state that earlier grants from 2016 through 2024 are fully vested, while an October 1, 2024 grant left 856,200 options vested at appointment and 1,198,800 options scheduled to vest in seven equal quarterly installments, subject to her continued service.
BioLineRx Ltd. director Raphael Hofstein filed an initial ownership report showing he holds several employee stock options over the company’s ordinary shares. This Form 3 does not report new purchases or sales, but lists option grants previously awarded under the company’s 2003 Amended and Restated Share Incentive Plan.
The disclosed positions include options exercisable at prices such as $0.8370, $0.9200, and as low as $0.0520 per share, with expiration dates ranging from July 2026 to August 2034. Footnotes state that most grants are already fully vested, while a large grant covering 2,055,000 underlying shares at $0.0520 has 856,200 options vested and 1,198,800 scheduled to vest in seven equal quarterly installments, contingent on his continued service.
BioLineRx Ltd. director Dar Rami reported initial holdings of employee stock options over Ordinary Shares. The Form 3 shows several option grants with exercise prices between $0.052 and $0.085, expiring between 2032 and 2034, granted under the 2003 Amended and Restated Share Incentive Plan.
One grant over 2,055,000 underlying shares at an exercise price of $0.052 includes 856,200 options vested as of the appointment date, with the remaining 1,198,800 vesting in seven equal quarterly installments, subject to continued service.